News Releases

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Servier Targets Transformative Treatment of Cancer at ASCO 2023

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio

Servier receives a positive CHMP opinion for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

Servier full year 2021/22 results confirm the transformation trajectory of the Group

Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium

Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia

Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022

Servier Wins Reuters’ 2022 Patient Champion Award

New Data at ASH 2022 Bolster Servier's Leadership in Hematology Research

Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston's Seaport

Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine

Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center

Servier Submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for Patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research